Polymethylmethacrylate membrane with a series of serendipity

Contributions to Nephrology

Volumn 173, Issue , 2011, Pages 137-147

  Sakai, Yoshitada ^a  

^a Toray Medical Company   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BIOMATERIAL; ENDOTOXIN; PLASMA PROTEIN; POLY(METHYL METHACRYLATE);

ADSORPTION; ARTICLE; ARTIFICIAL MEMBRANE; BLOOD; CHEMICAL PHENOMENA; CHEMICAL STRUCTURE; CHEMISTRY; DIFFUSION; HEMODIAFILTRATION; HUMAN; INSTRUMENTATION; MATERIALS TESTING; METABOLISM; MOLECULAR WEIGHT; PERMEABILITY; PRURITUS; RENAL REPLACEMENT THERAPY; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME; UREMIA;

ADSORPTION; BETA 2-MICROGLOBULIN; BIOCOMPATIBLE MATERIALS; BLOOD PROTEINS; DIFFUSION; ENDOTOXINS; HEMODIAFILTRATION; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MATERIALS TESTING; MEMBRANES, ARTIFICIAL; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; PERMEABILITY; POLYMETHYL METHACRYLATE; PRURITUS; RENAL DIALYSIS; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME; UREMIA;

EID: 84958591864     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000329052     Document Type: Article

References (32)

1. Sakai Y, Tanzawa H: Poly (methylmethacrylate) membranes. J Appl Polymer Sci 1978;22:1805-1815.
2. Sakai Y, Tsukamoto H, Fujii Y, Tanzawa H: Formation of poly (methylmethacrylate) membranes utilizing stereocomplex phenomenon; in Cooper AR (ed): Ultrafiltration Membranes and Applications. New York, Plenum Publishing, 1980, pp 99-107.
3. Ota K, Okazawa T, Kumagaya E, Sugino N, Mitani N, Fujii Y, Kimura M, Nagao Y, Tsukamoto H, Tanzawa H, Sakai Y: Polymethylmethacrylate capillary kidney highly permeable to middle molecules. Proc Eur Dial Transplant Assoc 1975;12:559-564.
4. Babb AL, Popovichi RP, Christopher TG, Scribner BH: The genesis of the square meter-hour hypothesis. Transact Am Soc Artif Intern Organs 1971;17:81-91.
5. Kunitomo T, Lowrie EG, O'Brien M, Lazarus JM, Gottlieb MN, Kumazawa S, Merrill JP: Performance and clinical use of a convertible hemodialysis- ultrafiltration system. Proc Dialysis Transplant Forum 1976;120-127.
6. Kunitomo T, Lowrie EG, Kumazawa S, O'Brien, Lazarus JM, Gottlieb MN, Merrill JP: Controlled ultrafiltration (UF) with hemodialysis (HD): analysis of coupling between convective and diffusive mass transfer in a new HD-UF system. Trans Am Soc Artif Intern Organs 1977;23:234-243.
7. Hakim RM, Fearon DT, Lazarus JM, Perzanowski CS: Biocompatibility of dialysis membranes: effects of chronic complement activation. Kidney Int 1982;26:194-200.
8. 2microglobulin on in vitro calcification of osteoblastic cells. Biochem Biophys Res Commun 1986;141:360-366.
9. 2-microglobulin. Biochem Biophys Res Commun 1985;129:701-706.
10. 2-microglobulin in chronic dialysis (HD) patients. Abstr Trans Am Soc Artif Intern Organs 1986:37.
11. 2-microglobulin removal by PMMA BK membrane. Nephrol Dial Transplant 1991(suppl 2):69-74.
12. 2-microglobulin Removal Membrane: Long-term clinical experience with PMMA membrane; in Ronco C (ed): Polymethylmethacrylate. A Flexible Membrane for a Tailored Dialysis. Basel, Karger, 1998, vol 125, pp 205-212.
13. Yamada S, Kataoka H, Kobayashi H, Ono T, Minakuchi J, Kawano Y: Identification of an erythropoietic inhibitor from the dialysate collected in the hemodialysis with PMMA membrane (BK-F) and its clinical effects; in Ronco C (ed): Polymethylmethacrylate. A Flexible Membrane for a Tailored Dialysis. Basel, Karger, 1998, vol 125, pp 159-172.
14. Niwa T, Miyazaki T, Maeda K. Removal of furancarboxylic acid, a protein-bound uremic toxin, by hemodialysis using largepore membrane dialyzer. Jpn J Artif Organs 1995;24:694-696.
15. Galli F, Benedetti S, Buoncristiani U, Piroddi M, Conte C, Canestrari F, Buoncristiani E, Floridi A; The effect of PMMA-based protein-leaking dialyzers on plasma homocysteine levels. Kidney Int 2003;64:748-755.
16. Galli F, Benedetti S, Floridi A, Canestrari F, Piroddi M, Buoncristiani E, Buoncristiani U: Glycoxidation and inflammatory markers in patients on treatment with PMMA-based protein-leaking dialyzers. Kidney Int 2005;67:750-759.
17. Suzuki M: Recent advances of highperformance membranes for hemodialysis. Membrane 1992;17:2-11 (Japanese).
18. Birk H-W, Kistner A, Wizemann V, Schütterle: Protein adsorption by artificial membrane materials under filtration condition. Artif Organs 1995;19:411-415.
19. Aoike I: Clinical significance of protein adsorbable membranes-long-term clinical effects and analysis using a proteomic technique. Nephrol Dial Transplant 2007;22(suppl 5):v13-v19.
20. Ishikawa I, Chikazawa Y, Sato K, Nakagawa M, Imamura H, Hayama S, Yamaya H, Asaka M, Tomosugi N, Yokoyama H, Matsumoto K: Proteomic analysis of serum, outflow dialysate and adsorbed protein onto dialysis membranes (polysulfone and PMMA) during hemodialysis treatment using SELDI-TOF-MS. Nephrology 2006;26:372-380.
21. Yamada S, Sugaya H, Aoike I, Ohbayashi H, Suzuki M, Yamagishi T, Kumagai M, Okada M, Shimada H, Nakagawa Y, Kutsuwada T, Gejyo F: Isolation of mast cell degranulation factor from dialysis patients with pruritus and its removal by dialysis membranes. Kidney Dial 2003;55(suppl):167-171 (Japanese).
22. Aucella F, Vigilante M, Gesuete A, Maruccio G, Specchio A, Gesualdo L: Uraemic itching: do polymethylmethacrylate dialysis membranes play a role? Nephrol Dial Transplant 2007;22(suppl 5):v8-v12.
23. Lin HH, Liu YL, Liu JH, Chou CY, Yang YF, Kuo HL, Huang CC: Uremic pruritus, cytokines, and polymethylmethacrylate artificial kidney. Artif Organs 2008;32:468-472.
24. Contin C, Pitard V, Delmas Y, Pelletier N, Defrance T, Moreau J-F, Merville P, Déchanet-Merville J: Potential role of soluble CD40 in the humoral immune response impairment of ureamic patients. Immunology 2003;110:131-140.
25. Contin-Bordes C, Lacraz A, de Precigout V: Potential role of the soluble form of CD40 in deficient immunological function of dialysis patients: new findings of its amelioration using polymethylmethacrylate membrane. NDT Plus 2010;3(suppl 1):i20-i27.
26. Cohen G, Rudnicki M, Schmaldienst S, Hörl W-H: Effect of dialysis on serum/plasma levels of free immunoglobulin light chains in end-stage renal disease patients. Nephrol Dial Transplant 2002;17:879-883.
27. Oshihara W, Nagao H, Megano H, Arai J, Koide M, Takada M: Trial use of a polymethylmethacrylate membrane for the removal of free immunoglobulin light chains in dialysis patients. NDT Plus 2010;3(suppl 1):i3-i7.
28. Masakane I: High-quality dialysis: a lesson from the Japanese experience. NDT Plus 2010;3(suppl 1):i28-i35.
29. Kreusser W, Reiermann S, Vogelbusch G, Bartual J, Schulze-Lohoff E: Effect of different synthetic membranes on laboratory parameters and survival in chronic haemodialysis patients. NDT Plus 2010;3(suppl 1):i12-i19.
30. Pisoni RL, Wikström B, Elder SJ, Akizawa T, Asano Y, Keen ML, Saran R, Mendelssohn DC, Young EW, Port FK: Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2006;21:3495-3505.
31. JSDT Statistical Committee: An overview of regular dialysis treatment in Japan as of December 31, 2009. Tokyo, JSDT, 2010, pp 73-74.
32. Vanholder R, Smet RD, Glorieux G, et al: Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-1943.